US 11667596
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
granted A61KA61K31/05A61K31/122
Quick answer
US patent 11667596 (2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders) held by PTC THERAPEUTICS, INC. expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/05, A61K31/122, A61P, A61P25/16